Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Baxter
Harvard Business School
Queensland Health
McKinsey
McKesson
Cipla
Daiichi Sankyo
Fish and Richardson

Generated: May 27, 2018

DrugPatentWatch Database Preview

HYTRIN Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Hytrin patents expire, and what generic alternatives are available?

Hytrin is a drug marketed by Abbott and is included in two NDAs.

The generic ingredient in HYTRIN is terazosin hydrochloride. There are twenty-four drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the terazosin hydrochloride profile page.
Summary for HYTRIN
Drug patent expirations by year for HYTRIN
Synonyms for HYTRIN
(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(tetrahydrofuran-2-yl)methanone hydrochloride
[4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-tetrahydrofuran-2-yl-methanone hydrochloride
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone hydrochloride
074T088
1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)-piperazine hydrochloride
1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonxyl]piperazine Hydrochloride
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]-piperazine hydrochloride
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride
141269-45-6
2[4-(Tetrahydro-2-furoy1)piperazinyl]-4-amino-6,7-dimethoxyquinazoline hydrochloride
4-Amino-6,7-dimethoxy-2-[4-(tetrahydro-2-furoyl)-1-piperazinyl]quinazoline Hydrochloride
6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-amine hydrochloride
63074-08-8
63590-64-7 (Parent)
AB1009460
AB2000463
Abbott-45975
AC-2074
AC1L2BPY
AK307521
AKOS007930686
AN-14324
BB_SC-1129
C19H25N5O4.HCl
CAS-63074-08-8
CCG-220751
CHEMBL1256665
DB-018541
DSSTox_CID_25493
DSSTox_GSID_45493
DSSTox_RID_80913
DTXSID7045493
EU-0101138
FT-0605647
HMS1570G04
I06-0651
IWSWDOUXSCRCKW-UHFFFAOYSA-N
KS-00000JKM
LP01138
LS-110235
MFCD00467965
MLS000040261
MLS001077301
MLS001305722
MolPort-003-666-790
NCGC00016026-10
NCGC00016903-01
NCGC00094404-01
NCGC00094404-02
NE45355
NSC-759168
NSC759168
Opera_ID_398
Pharmakon1600-01505576
Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)-, monohydrochloride
Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)-,monohydrochloride
Prestwick_146
s4679
SCHEMBL41545
SMR000044015
T 4680
Terazosin HCl
Terazosin hydrochloride
TERAZOSIN HYDROCHLORIDE (anhydrous)
Terazosin hydrochloride anhydrous
Terazosin hydrochloride, >=98% (TLC), powder
Terazosin monohydrochloride anhydrous
terazosine hydrochloride
terazosinhydrochloride
Tetrazosin hydrochloride
TL8004930
Tox21_110674
Tox21_110674_1
TR-037527
TRA0127916
V1531
VA11840
Vasocard
Zayasel

US Patents and Regulatory Information for HYTRIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbott HYTRIN terazosin hydrochloride CAPSULE;ORAL 020347-001 Dec 14, 1994 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Abbott HYTRIN terazosin hydrochloride TABLET;ORAL 019057-003 Aug 7, 1987 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Abbott HYTRIN terazosin hydrochloride CAPSULE;ORAL 020347-004 Dec 14, 1994 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Abbott HYTRIN terazosin hydrochloride TABLET;ORAL 019057-004 Aug 7, 1987 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for HYTRIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbott HYTRIN terazosin hydrochloride TABLET;ORAL 019057-003 Aug 7, 1987 ➤ Try a Free Trial ➤ Try a Free Trial
Abbott HYTRIN terazosin hydrochloride TABLET;ORAL 019057-001 Aug 7, 1987 ➤ Try a Free Trial ➤ Try a Free Trial
Abbott HYTRIN terazosin hydrochloride CAPSULE;ORAL 020347-002 Dec 14, 1994 ➤ Try a Free Trial ➤ Try a Free Trial
Abbott HYTRIN terazosin hydrochloride CAPSULE;ORAL 020347-001 Dec 14, 1994 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
McKesson
AstraZeneca
Farmers Insurance
McKinsey
Accenture
Covington
Healthtrust
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.